Strides Pharma Science Limited has announced a meeting of its Board of Directors on January 30, 2026. The primary agenda is to review and approve the unaudited financial results for the quarter and nine months ending December 31, 2025. The announcement confirms that trading window for designated persons is closed from January 1, 2026, and will reopen 48 hours after the results are declared.
Board Meeting for Financial Review
A meeting of the Board of Directors at Strides Pharma Science Limited is scheduled for January 30, 2026. The board will consider and approve the unaudited financial results of the company. These results cover both standalone and consolidated figures.
Financial Period Under Review
The financial performance being reviewed at the board meeting pertains to the quarter and nine-month period which ended on December 31, 2025. This includes a comprehensive assessment of the company’s financial standing.
Insider Trading Restrictions
As per company policy, the trading window for designated persons has been closed starting from January 1, 2026. This restriction is in place to prevent insider trading and will remain until 48 hours after the declaration of the financial results.
Access to Information
Further details regarding the company and its results will be available on the company’s website at www.strides.com.
Source: BSE
